Compound erythromycin sustained release preparation and its in vitro release.
- Author:
Hai-xia CHEN
1
;
Zhi-peng CHEN
;
Qi-rong WANG
;
Ze-kun LIU
;
Quan-long MA
Author Information
1. Department of Pharmacy of the Qilu Hospital of Shandong University, Jinan 250012, China.
- Publication Type:Journal Article
- MeSH:
Chromatography, High Pressure Liquid;
Delayed-Action Preparations;
administration & dosage;
chemistry;
therapeutic use;
Drug Carriers;
Drug Combinations;
Erythromycin;
administration & dosage;
chemistry;
therapeutic use;
Humans;
Lactic Acid;
administration & dosage;
Polyesters;
Polymers;
administration & dosage;
Prednisone;
administration & dosage;
chemistry;
therapeutic use;
Sinusitis;
drug therapy;
Spectrophotometry, Ultraviolet;
Tablets
- From:
Acta Pharmaceutica Sinica
2011;46(11):1385-1389
- CountryChina
- Language:Chinese
-
Abstract:
Using the weight-average molecular weight 50 000 polylactic acid (PLA) as a carrier, and a certain proportion of erythromycin (EM) and prednisone acetate (PNA) to mixed prepare the compound erythromycin sustained release preparation (sustained-release tablets). Using ultraviolet spectrophotometry and high performance liquid chromatography (HPLC) to detect separately the release amount of EM and PNA in vitro medium. The sustained-release tablets release for about 21 days, the average content of EM is 99.7 mg/table, RSD = 0.82%; and the average content of PNA is 10.03 mg/table, RSD = 0.93%. Within 21 days, the cumulative releases of EM and PNA are 86.1% and 78.3%, respectively. The drug release is steady and slow after 5 days, the burst release phenomenon in early stage is more significant. The results showed that the sustained-release tablet preparation method is feasible, the release performance is good and the clinical efficacy is significant.
